HALETHORPE, Md., May 16, 2025 ~ Fzata, Inc., a biotechnology company focused on developing oral biologics for gastrointestinal (GI) disorders, has announced its attendance at the BIO International Convention 2025 in Boston. The company's main objective at the convention is to find a pharmaceutical partner for their preclinical therapeutic, FZ006, which shows promise in treating inflammatory bowel disease (IBD).

FZ006 is a first-in-class yeast therapeutic that delivers an anti-TNF-a monoclonal antibody directly to the gut through oral administration. This localized delivery method is expected to provide the same effectiveness as current treatments like Humira® and Remicade®, but with a more favorable safety profile, increased convenience, and improved patient compliance. FZ006 has the potential to be the first anti-TNF-a therapy approved for treating all levels of IBD severity.

In addition to their attendance at the convention, Fzata is pleased to announce that saxophonist and Crohn's disease patient Antonio Hancock, known by his stage name Saxl Rose, will be joining forces with the company as an IBD patient advocate. Hancock's personal experience with IBD and his passion for finding more convenient treatment options make him an ideal partner for Fzata.

More on Boston Chron

• Boston: Updates on Transformative Investments in Mental Health Services and Programs for Youth and Families
• AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million
• King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
• Labthink's Medford Lab is Open for Testing Services for Flexible Packaging Materials
• A Global First: NaturismRE™ Launches the Global Urgency Index

Dr. Zhiyong Yang, CEO and Co-Founder of Fzata, stated that their oral biologics are designed with patients' needs in mind. He believes that FZ006 has the potential to fill a crucial gap in IBD treatment by combining the potency of biologic therapies with the ease and safety of an oral medication.

Hancock also expressed his excitement about partnering with Fzata and supporting their innovative approach to treating IBD. As someone who receives infusions every eight weeks for his Crohn's disease, he understands firsthand the challenges of scheduling life around medical treatments. He believes that Fzata's work could greatly benefit not only busy individuals like himself, but also anyone who prefers the convenience of oral medication.

Throughout the convention, Fzata will be participating in BIO's One-on-One Partnering™ meetings. Interested investors and strategic partners are encouraged to contact Elizabeth Smith for more information and to schedule meetings with the company. With their groundbreaking approach to treating IBD and the support of advocates like Hancock, Fzata is poised to make a significant impact in the field of biotechnology.

---

Show All News | Report Violation